Legal status · Australia
Is Pegcetacoplan legal in Australia?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
Yes. Pegcetacoplan is an approved medicine in Australia, classified as "Registered for the blood indication only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Pegcetacoplan in Australia at a glance
| Classification | Registered for the blood indication only |
|---|---|
| Note | The geographic atrophy product is not available on the same basis as in the United States. Prescription only, specialist use. |
| TGA approval status | Approved by TGA for its labeled use |
| Human studies cited | 4 of 4 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Pegcetacoplan profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
TGA has approved Pegcetacoplan for at least one labeled indication, so a pharmaceutical-grade product exists in Australia and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Pegcetacoplan is
The same molecule holds two unrelated approvals: subcutaneous Empaveli for paroxysmal nocturnal haemoglobinuria, where it beat eculizumab by 3.84 g/dL of haemoglobin at 16 weeks, and intravitreal Syfovre for geographic atrophy, where it slowed lesion growth by 16 to 22 percent and showed no difference on any visual function endpoint at 24 months. European regulators refused the eye indication on exactly that point.
Pegcetacoplan is a symmetrical construct of two identical 13-residue cyclic peptides joined by a 40 kDa linear polyethylene glycol linker. Most of its mass is the PEG.
Mechanism: Binding to complement C3 and its activation fragment C3b, preventing cleavage of C3 and therefore blocking the common step shared by the classical, lectin and alternative complement pathways. Because C3 is upstream of C5, inhibition removes both the terminal membrane attack complex that lyses red cells in the circulation and the C3b opsonisation that tags them for removal by the liver and spleen.
Regulatory history: FDA-approved twice. Empaveli, NDA 215014, approved 14 May 2021, subcutaneous infusion, for paroxysmal nocturnal haemoglobinuria in adults and now also for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis from age 12. Syfovre, NDA 217171, approved 17 February 2023, intravitreal injection, for geographic atrophy secondary to age-related macular degeneration. The European Medicines Agency refused the geographic atrophy indication in 2024.
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Pegcetacoplan at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Pegcetacoplan in other countries
Frequently asked questions
Is Pegcetacoplan legal in Australia?
Yes. Pegcetacoplan is an approved medicine in Australia, classified as "Registered for the blood indication only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: The geographic atrophy product is not available on the same basis as in the United States. Prescription only, specialist use.
Can I buy Pegcetacoplan in Australia?
Only with a prescription. Pegcetacoplan is classified as "Registered for the blood indication only" in Australia, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection. Note: The geographic atrophy product is not available on the same basis as in the United States. Prescription only, specialist use.
Is Pegcetacoplan TGA approved?
Yes, for its labeled indication. In Australia Pegcetacoplan is classified as "Registered for the blood indication only". For comparison, the US FDA status is: FDA-approved twice. Empaveli, NDA 215014, approved 14 May 2021, subcutaneous infusion, for paroxysmal nocturnal haemoglobinuria in adults and now also for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis from age 12. Syfovre, NDA 217171, approved 17 February 2023, intravitreal injection, for geographic atrophy secondary to age-related macular degeneration. The European Medicines Agency refused the geographic atrophy indication in 2024.. On the evidence, 4 human studies are cited on its profile.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Pegcetacoplan live on its compound profile.
Pegcetacoplan profileThis page is general information about the regulatory status of Pegcetacoplan in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.